Senseonics to Showcase Innovations at Healthcare Conference
In a significant development for the medical technology field, Senseonics Holdings, Inc. (NYSE American: SENS) is set to participate in the upcoming Stifel 2025 Healthcare Conference in New York. This conference is a pivotal platform that allows companies to present their latest innovations to investors and industry leaders, highlighting their contributions to health management technologies.
Details of the Conference Participation
The format of this year’s Stifel Healthcare Conference includes a fireside chat and one-on-one meetings, offering an excellent opportunity for Senseonics to connect directly with key stakeholders. The event is scheduled for Wednesday and will commence at 4:40 PM ET. Industry followers and stakeholders are encouraged to tune into the live webcast, which promises to deliver insights into the company's strategic initiatives and product offerings.
Live Webcast Accessibility
For those unable to attend in person, a live and recorded webcast will be available on Senseonics' official website in the "Investor Relations" section. This allows potential investors and interested parties to gain real-time access to the presentation and absorb the insightful dialogue surrounding advances in glucose monitoring technology.
Understanding Senseonics' Mission
Senseonics is at the forefront of transforming diabetes management through its innovative products. The company is dedicated to developing long-term, implantable continuous glucose monitoring (CGM) systems that significantly improve the quality of life for people living with diabetes. Their flagship CGM systems, Eversense® 365 and Eversense® E3, are designed to provide accurate and real-time glucose readings, helping users manage their condition effectively.
Product Features and Benefits
The Eversense systems stand out with their unique technology: a small sensor is implanted under the skin, seamlessly communicating with a wearable smart transmitter. This transmitter sends glucose data every five minutes to a mobile application on the user’s smartphone, allowing for convenient monitoring and management. Such technology not only enhances user experience but also empowers individuals to take control of their health.
Investor Engagement and Contact Information
Senseonics believes in maintaining transparent communication with its investors and the public. As it continues to innovate and expand its offerings, Engage with the company through their Investor Relations point of contact, Jeremy Feffer at LifeSci Advisors, who is available to address inquiries regarding investment opportunities and product information.
Why This Matters for Investors
As the diabetes technology landscape continues to evolve, Senseonics Holdings, Inc. (NYSE: SENS) is strategically positioned to lead the way. Participating in key events like the Stifel Healthcare Conference showcases their commitment to advancing diabetes care. Investors looking for opportunities in the health tech space should consider monitoring the outcomes of this conference as it could provide significant insights into future growth and developments within the company.
Frequently Asked Questions
What is the main focus of Senseonics Holdings, Inc.?
Senseonics is dedicated to developing and manufacturing long-term glucose monitoring products for diabetes management.
When will Senseonics present at the Stifel Healthcare Conference?
Senseonics is scheduled to present on Wednesday at 4:40 PM ET during the conference.
How can I access the presentation from the conference?
Participants can access the live and recorded webcast through the Investor Relations section of Senseonics' official website.
What type of products does Senseonics offer?
They offer implantable continuous glucose monitoring systems, including the Eversense® 365 and Eversense® E3.
Who can I contact for investor inquiries about Senseonics?
For investor inquiries, contact Jeremy Feffer at LifeSci Advisors via the email investors@senseonics.com.
